SCHEMBL7122490

SCHEMBL7122490

CCCc1c(OC2CCCC2)c2cc(C)ccc2[nH]c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.62
TSHR P16473 1/20 0.62
MAPT P10636 3/20 0.55
HTT P42858 2/20 0.55
KDM4E B2RXH2 6/20 0.45
RECQL P46063 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 3/20 0.41
PDE9A O76083 2/20 0.41
TP53 P04637 1/20 0.41
PIM1 P11309 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
SIRT1 Q96EB6 2/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119334 0.87 HSD17B10 (0.45) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7116744 0.87 SIRT1 (0.46) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7124940 0.87 HSD17B10 (0.45) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7124010 0.86 SIRT1 (0.45) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7117392 0.86 HSD17B10 (0.48) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7114914 0.84 SIRT1 (0.46) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7119105 0.84 MEN1 (0.53) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7114098 0.84 PDE9A (0.58) HSD17B10TSHRKDM4ESMN1; SMN2RAB9A
SCHEMBL7125625 0.82 KDM4E (0.43) HSD17B10TSHRMAPTHTTKDM4E
SCHEMBL7552947 0.80 SIRT1 (0.40) HSD17B10TSHRMAPTKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP claimed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 HSD17B10 1601/4885TSHR 4728/4885MAPT 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.